The concept of health has a much broader meaning at Chiesi and also encompasses that of the planet. This is also because the health of the planet and that of its inhabitants are interdependent. We therefore aim to act as a force for good and reduce the negative impacts on the areas where we operate.
We want to adopt a model based on responsible consumption and production in order to reduce our impact on the environment and conserve our resources for future generations. In 2019, with this in mind, we publicly announced our decision to become carbon neutral by the end of 2035, well in advance of 2050, the year set down in the Paris Agreement. This is the first universal and legally binding international agreement on climate change and was adopted at the Paris climate conference (COP21) in December 2015.
One of the most important projects in this area is an investment plan providing €350 million to introduce the first low carbon content pMDI by the end of 2025. This project is based on the use of a new generation propellant with a low Global Warming Potential to reduce the carbon footprint of our pMDIs by 90%. Despite the fact that the pharmaceutical use of HFAs makes an extremely limited contribution to global CO2 emissions, we are strongly committed to carrying out this 5-year plan aimed at safeguarding patient choice and the environment. Our new headquarters in Parma was designed and built to be eco-sustainable and provides for thermal energy recovery systems, the use of renewable energy and a green area extending over more than 6,000 m2.
Lastly, we are committed to adopting a model based on responsible consumption and production. Our Sustainable Chemistry Policy is dedicated to the responsible management of chemical substances used for research activities and safeguards both the environment and our employees whilst also ensuring the highest health and safety standards.
In order to meet this objective, various strategies have been implemented, including greater use of renewable energies and transportation suppliers that are able to quantify their CO2 emissions and are also committed to reducing their environmental impact. We have also calculated the environmental impact of our products using the Carbon Footprint Systematic Approach tool. This tool enables us to analyse the entire life cycle of our pressurised metered-dose inhalers (pMDI) – whose impact is mainly due to the GWP (Global Warming Potential) of hydrofluoroalkane (HFA) propellants – and dry powder inhalers (DPI), as well as gauging future impact beginning from the research and development phase by providing adequate planning to improve product performance for patients and the environment.